Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month supply online for ... be scheduled at the 30-day interval from their initial ...

Have the markets overreacted to bad guidance? When a stock falls more than 40% on a single day, as DexCom did due to underwhelming guidance, it's hard to not call that an overreaction in the markets.

In March, the FDA cleared Dexcom’s Stelo, making it the first ... showing when users’ glucose levels spike and ebb throughout the day. “When someone sees their own personal data, that ...

This year started with healthy gains for DexCom (NASDAQ: DXCM) stock, but they didn't last long. The medical device stock is now down by about 53% from the high-water mark it set in April.

Shares of DexCom Inc. DXCM rallied 3.70% to $68.11 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.90% to 5,751.07 ...

Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ ... blood glucose levels efficiently throughout the day, has been linked with better outcomes.

Shares of DexCom Inc. DXCM shed 1.88% to $73.44 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.03% to 5,808.12 and Dow ...

Here's why you should take advantage. DexCom ( NASDAQ:DXCM ) Third Quarter 2024 Results Key Financial Results Revenue: US$994.2m (up 2.0% from 3Q 2023). Net... Dexcom stock closed in the red on ...

With a market cap of $27.1 billion, DexCom, Inc. (DXCM) is a leading medical device company, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The San Diego ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...